Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 2

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 2
---
 are unable to  

  Significant disruptions of our information technology systems or breaches of our data security could adversely  

  We deal with hazardous materials and must comply with environmental, health and safety laws and regulations,  

  We are currently party to, and may in the future, become subject to litigation or claims arising in or                 
  outside the ordinary course of business that could negatively affect our business operations and financial condition.  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

2

Risks Related to Intellectual Property

  Our access to most of the intellectual property associated with our therapeutic candidates                                                        

Risks Related to our Ordinary Shares and ADSs

  Our business, operating results and growth rates may be adversely affected by current or future unfavorable                    
  economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk.  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  The market prices of our ordinary shares and ADSs are subject to fluctuation, which could result in substantial  

  Future sales of our ordinary shares or ADSs could reduce the market price of our ordinary shares and ADSs.  

  Raising additional capital by issuing securities may cause dilution to existing shareholders.  
 ─────────────────────────────────────────────────────────────────────────────────────────────────

  If we fail to comply with the continued listing requirements of the Nasdaq, our ADSs may be delisted and  
  the price of our ADSs and our ability to access the capital markets could be negatively impacted.         
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────

Risks Related to our Operations in Israel

  We conduct a substantial part of our operations in Israel and therefore our results may be adversely affected                          
  by political, economic and military instability in Israel and its region.                                                              
  Provisions of Israeli law may delay, prevent or otherwise impede a merger with, or an acquisition of, our                              
  company, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  It may be difficult to enforce a U. S. judgment against us and our officers and directors in Israel or the  
  United States, or to serve process on our officers and directors.                                           
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────